GT BIOPHARMA, INC. Investments and Cash
GT BIOPHARMA, INC. (GTBP) had Investments and Cash of $19.90 million as of 2023-03-31, per its 10-Q filed 2023-05-15.
Discontinued › Balance Sheet › Assets
us-gaap:InvestmentsAndCash · last filed 2023-05-15
- 2023-03-31: Investments and Cash $19.90M.
- 2022-12-31: Investments and Cash $23.00M.
- 2022-09-30: Investments and Cash $20.80M.
- 2022-06-30: Investments and Cash $23.70M.
| Period end | Investments and Cash |
|---|---|
| 2023-03-31 | $19.90M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $23.00M 10-K · filed 2023-03-30 |
| 2022-09-30 | $20.80M 10-Q · filed 2022-10-31 |
| 2022-06-30 | $23.70M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $26.70M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $32.00M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |